By D. G. Oreopoulus (auth.), Dimitrios G. Oreopoulos MD (eds.)
The yr was once 1943. As a third-year clinical pupil at Stanford, i used to be approximately to witness the start of a clinical miracle. Dr. Arthur Bloomfield, Professor of medication, had chosen my sufferer, a center elderly guy, who used to be death of acute pneumococcal pneumonia, as one of many first sufferers to obtain miniscule doses (by cutting-edge criteria) of his meagre provide of a brand new drug - penicillin. The patient's reaction surprised each person specially this impressionable scientific pupil. the remainder of the tale is heritage. With one stroke, the advent of penicillin faraway from the scientific scene the 'friend of the elderly' - lobar pneumonia. the implications, which not anyone can have imagined on the time, are nonetheless changing into happen as different 'miracles' similar to respirators, man made kidneys and lots of effective new antibiotics have come across the scene. we all are acutely aware that those miracles have created numerous new demanding situations round the states of demise and close to loss of life. we haven't any effortless solutions for those difficulties. however as dialysis concepts, in particular CAPD, are utilized extra broadly to the remedy of the aged, the duty of supporting the sufferer meet loss of life with dignity turns into more and more vital and vexing simply because as soon as started, dialysis is tough to terminate.